MBX 2109 (Part A) for Healthy Subjects

Phase-Based Progress Estimates
Healthy SubjectsMBX 2109 (Part A) - Drug
21 - 60
All Sexes
What conditions do you have?

Study Summary

This trial is evaluating the safety and tolerability of a new drug called MBX 2109 given as a shot under the skin. The study will also look at how well the drug is absorbed and how it affects the body.

Video Summary

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline through Day 40 (part A) or Day 60 (Part B)

Day 60
Measures 1
Measures 2

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

MBX 2109 (Part B)
1 of 3
MBX 2109 (Part A)
1 of 3
1 of 3

Experimental Treatment

Non-Treatment Group

80 Total Participants · 3 Treatment Groups

Primary Treatment: MBX 2109 (Part A) · Has Placebo Group · Phase 1

MBX 2109 (Part B)
Experimental Group · 1 Intervention: MBX 2109 (Part B) · Intervention Types: Drug
MBX 2109 (Part A)
Experimental Group · 1 Intervention: MBX 2109 (Part A) · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through day 40 (part a) or day 60 (part b)

Who is running the clinical trial?

MBX BiosciencesLead Sponsor
Mary Jane Geiger, MD, PhDStudy DirectorMBX Biosciences

Eligibility Criteria

Age 21 - 60 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
There were no clinically significant findings on the patient's physical examination, electrocardiogram, laboratory tests or vital signs.
The subject has been given permission to participate in the study after signing an informed consent form.
People with a BMI between 20.0 and 32.0 kg/m2 are considered to be of a healthy weight.
Healthy individuals between the ages of 20 and 60, both men and women, who are not able to have children.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Labcorp Drug Development: Clinical Research Unit100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Typically responds via
Phone Call100.0%
Most responsive sites:
  1. Labcorp Drug Development: Clinical Research Unit: < 24 hours
Average response time
  • < 1 Day